Barclays started coverage of Abbott Laboratories stock with USD 120 target
Published on 10/12/2026 at 11:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Barclays started coverage of Abbott Laboratories with an Overweight rating and a USD 120.00 price target on October 7, 2026.
- Revenue reached USD 12.59 billion in the second quarter, up 13.00 percent year over year.
- Abbott Laboratories stock was trading at EUR 89.38 at Lang & Schwarz on October 12, 2026, versus the Xetra close of EUR 88.86 on October 9, 2026.
- Abbott is scheduled to report third-quarter 2026 results on October 21, 2026, before the US market opens.
Abbott Laboratories (ISIN US0028241000) was trading at EUR 89.38 at Lang & Schwarz on October 12, 2026 at 11:21 a.m. CEST. The company remains anchored by a recent Barclays initiation: the bank started coverage with an Overweight rating and a USD 120.00 price target on October 7, 2026, according to MarketBeat.
Barclays sets a USD 120 target
Barclays' target gives the latest analyst view a concrete benchmark. MarketBeat reported that the USD 120.00 target implied 22.27 percent upside from the reference share price on October 7, 2026, while the broader consensus stood at Moderate Buy with an average target of USD 118.88.
Investing.com reported on October 2, 2026 that Rothschild and Co Redburn upgraded Abbott from Neutral to Buy and raised its target from USD 119.00 to USD 127.00. The analyst cited medical devices growth and the contribution of the Exact Sciences acquisition to Abbott's diagnostics profile.
What does the target mean for growth?
The operating backdrop includes a sizable reported-growth comparison. Abbott's revenue reached USD 12.59 billion in the second quarter of 2026, up 13.00 percent from the same quarter a year earlier, while adjusted earnings per share came to USD 1.31 against a USD 1.28 consensus estimate, according to MarketBeat.
The next test is dated October 21, 2026. Abbott said on September 30, 2026 that it will announce third-quarter 2026 results before the US market opens, followed by a conference call.
Three dated milestones shape the setup
On July 16, 2026, Abbott reported second-quarter revenue of USD 12.59 billion and adjusted earnings per share of USD 1.31, according to MarketBeat. On September 17, 2026, the company declared a quarterly dividend of USD 0.63 per share, and on October 7, 2026, Barclays set its USD 120.00 target.
Abbott Laboratories was trading at EUR 89.38 at Lang & Schwarz on October 12, 2026 at 11:21 a.m. CEST, up EUR 0.52 or 0.59 percent versus the Xetra close of EUR 88.86 on October 9, 2026. The primary listing is on the NYSE in USD, while the current German-market reference is the Lang & Schwarz euro quote. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories stock facts
- Company: Abbott Laboratories
- ISIN: US0028241000
- WKN: 850103
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 12, 2026, 11:21 a.m. CEST: EUR 89.38
- Change versus Xetra close: plus 0.59 percent
- Xetra close October 9, 2026: EUR 88.86
- Market capitalization: EUR 154.5 billion as of October 12, 2026
- 52-week range: EUR 70.10-116.00 as of October 12, 2026
- Sector / Industry: Health Care
- Next earnings date: October 21, 2026
Market context: Market report S&P 500.
